Indian CRDMOs timed their IPOs right. But is the business worth the premium?


An anticipated shift in the global pharmaceutical supply chain away from China has investors excited about Indian contract research, development and manufacturing organisations (CRDMOs), companies that offer services from early-stage drug discovery to late-stage drug development.

Export-focused CRDMOs including Anthem Biosciences, Sai Life Sciences and Divi’s Laboratories are trading at expensive valuations, reflecting investor enthusiasm as innovator drug companies look at diversifying and derisking their operations. However, experts cautioned that while CRDMOs are expected to post high growth, their financial performances have yet to reflect it.

Bengaluru-based Anthem Biosciences made a stellar debut on the stock exchanges on 21 July, listing on the National Stock Exchange at a premium of 27 percent over its initial public offering price of 570. The IPO, with an issue size of 3,395.79 crore, was subscribed 67.42 times. Anthem’s stock traded at a price-to-earnings (PE) ratio of 93.24 on 25 July.

Event Title: International Conference on Strategic Management and Business Strategy

Website Link
Nominate here
Registration link:

Social Media Link
Facebook
Twitter
Pinterest
Blog
Youtube




Comments

Popular posts from this blog

Standing down from Falcon 9’s launch of Ax-4: SpaceX

‘London is back:’ Mayor — and Trump critic — Sadiq Khan looks to lure businesses from the U.S.

Meta recruits leading OpenAI researcher Trapit Bansal for AI reasoning lab